Provider & Caregiver Connection™: Patient Perspectives in Nontuberculous Mycobacterial Lung Disease

Released On
July 31, 2019

Expires On
July 31, 2020

Media Type

Completion Time
90 minutes

Pulmonology, Infectious Disease

Nontuberculous mycobacteria

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

Supported by an educational grant from Insmed Incorporated.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.5 contact hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for primary care physicians, infectious disease specialists, and pulmonologists. Physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of NTM-LD will also be invited to participate.

Program Overview

Nontuberculous mycobacteria (NTM) are mycobacteria that are not members of the species Mycobacterium tuberculosis or Mycobacterium leprae. Nontuberculous mycobacteria are ubiquitous in nature and most commonly isolated from soil and water, but also are found in biofilms coating the inside of showerheads. Exposure to environmental sources of NTM can lead to opportunistic infections, including severe pulmonary infections, and are especially common among those with genetic host defense defects and/or comorbidities, and negatively impact quality of life in those affected. Nontuberculous mycobacteria lung disease (NTM-LD) typically affects individuals age ˃60 years, and women are more likely than men to be affected. These mycobacteria are slow-growing pathogens, and many symptoms of NTM-LD, such as coughing, dyspnea, weight loss, and fatigue, mimic symptoms of such other respiratory ailments as bronchitis or chronic obstructive pulmonary disease, causing significant delays in diagnosis and appropriate treatment. Prevalence of NTM-LD is increasing in all regions of the United States and is especially prevalent along coastal regions.

This educational activity is highlighted with a patient’s perspective, from a 6-year journey to diagnosis, treatment challenges, lifestyle changes, and ongoing disease management. Two expert faculty will build on the patient’s narrative to share their experiences and practical insights on diagnosis with specific laboratory requirements, radiologic and clinical findings, and then current, new, and emerging treatments for this lifelong disease.

Benefits of Participating

  • Gain awareness and understanding of NTM-LD through a patient’s narrative from diagnosis to treatment
  • Understand the 3-pronged approach to diagnosis through laboratory, radiologic, and clinical findings
  • Recognize toxicities and monitoring requirements for standard treatment regimens
  • Learn about new and emerging treatments for refractory disease
  • Improve patient outcomes with strategies to individualize disease management

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the diagnostic approach to NTM-LD, including mycobacterial subspecies identification and evaluation of drug resistances
  • Evaluate the efficacy, toxicity, and drug interactions of antibiotics used in the treatment of NTM-LD
  • Incorporate patient perspectives into management of care and strategies to improve outcomes


Doreen J. Addrizzo-Harris, MD

Professor of Medicine, NYU School of Medicine
Associate Division Director, Education and Faculty Affairs
Division of Pulmonary, Critical Care and Sleep Medicine
Program Director, Pulmonary and Critical Care Fellowship
Co-Director, NYULMC Pulmonary Associates
NYU Langone Health
New York, NY

Ashwin Basavaraj, MD, FCCP

Associate Director, Bronchiectasis Program
Assistant Program Director, Pulmonary Fellowship
NYU Langone Health
New York, NY

Dariel Kirk (Patient Interviewee)

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest

Doreen J. Addrizzo-Harris, MD

  • Consultant: AIT Therapeutics.

Ashwin Basavaraj, MD, FCCP

  • Consultant: Insmed Phamaceuticals (Consultant and Advisory Board), Hill-Rom.

Dariel Kirk (Patient Interviewee)

  • No relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Method of Participation

Instructions for This Activity and Receiving Credit

  1. You will need to log in to participate in the activity.
  2. Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  3. At the end of the activity, educational content/audio files will be available for your reference.
  4. In order to receive a CME/CE certificate, you must complete the activity.
  5. Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure of Unlabeled Use

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.